Healthcare entity
Hims & Hers Health is most often covered alongside Novo Nordisk, which appears in 3 of these 4 stories. That works out to roughly 0.2 stories per week across a 163-day span. The busiest single day carried 2. Coverage clusters in telehealth, which accounts for 3 of those 4, with the remainder spread across 1 other category.
Last mentioned: 6d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Hims & Hers Health is most often covered alongside Novo Nordisk, which appears in 3 of these 4 stories. That works out to roughly 0.2 stories per week across a 163-day span. The busiest single day carried 2. Coverage clusters in telehealth, which accounts for 3 of those 4, with the remainder spread across 1 other category. At 6.3, the average consequence score sits above the same-window beat average of 6. They are less corroborated than the beat average, carrying 3 original sources each against 3.5 for the same window. This profile follows 4 Healthcare stories mentioning Hims & Hers Health across the period from March 9, 2026 to August 18, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 906 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Hims & Hers Health. Shared-story counts are live from our verified record — not editorial picks.
Hims & Hers posted 38% revenue growth and 2.89M subscribers while absorbing $81M in nonrecurring charges, and Alcon's core EPS rose 9% to $0.84. Telehealth demand and ocular health innovation are driving divergent profit outcomes.
Hims & Hers Health has secured a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The deal marks a pivotal shift for the telehealth provider from compounded alternatives to FDA-approved Ozempic, triggering a massive 41% rally in its share price.
Source: fool.com · Josh Kohn-Lindquist (us)
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages.
Hims & Hers Health and Novo Nordisk have resolved their legal dispute over compounded weight loss medications, announcing a surprise collaboration instead. This settlement marks a significant shift in the GLP-1 market, moving from aggressive litigation to a strategic alliance between a telehealth leader and a pharmaceutical giant.
Hims & Hers Health is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
